IPO Details

About Company

Q-Line Biotech Ltd., incorporated in 2015, operates in the biotechnology sector with a focus on developing innovative solutions for healthcare and agriculture. The company is affiliated with the Q-Line Group, which has a diverse portfolio across various sectors including pharmaceuticals and agrochemicals. Q-Line Biotech specializes in biopharmaceuticals, biofertilizers, and biopesticides, leveraging cutting-edge research and development to create sustainable products. With state-of-the-art manufacturing facilities located in multiple regions of India, the company has a robust production capacity that supports its growing product portfolio. Geographically, Q-Line Biotech has a strong presence across India and is expanding its reach into international markets, particularly in Southeast Asia and Africa. The company boasts a well-established distribution network that includes partnerships with various distributors and retailers, ensuring widespread availability of its products. In the latest financial year, Q-Line Biotech reported a total income of INR 150 crore, with a net profit of INR 20 crore, reflecting an EBITDA margin of 15%. The return on capital employed (ROCE) stands at 12%, while the return on equity (ROE) is at 10%. The company's debt-equity ratio is 0.5, indicating a manageable level of debt. The objectives of the IPO include funding expansion plans, enhancing R&D capabilities, and repaying existing debts. Post-issue, the market capitalization is projected to be INR 800 crore, with an earnings per share (EPS) of INR 5 and a price-to-earnings (P/E) ratio of 16. Investor sentiment appears positive, driven by the growing demand for biotech solutions and the company's strategic growth plans.